Sign In
Buy SNY
$44.38
+2.01 (+4.74%)
At Close: Jun 04, 2026
Sanofi lifts earnings outlook on Dupixent sales, new drug launches
01:42am, Friday, 28'th Jul 2023
French drugmaker Sanofi on Friday increased its guidance for full-year earnings on strong sales of anti-inflammatory treatment Dupixent and promising new drug launches.
7 Blue-Chip Stocks That Are Screaming Buys Right Now: July 2023
12:05pm, Sunday, 23'rd Jul 2023
While it's usually the smaller enterprises that offer screaming buy opportunities for discerning speculators, sometimes even the best blue-chip stocks to buy don't get the attention they deserve. With
Sanofi expects infant RSV shot to roll out before respiratory virus season this fall
05:08pm, Friday, 21'st Jul 2023
Sanofi said it is working with a CDC panel to include Beyfortus on the childhood immunization schedule and the Vaccines for Children Program.
Sanofi: Powering Up And Offering Investors A Lot Of Potentials
02:10pm, Thursday, 20'th Jul 2023
Sanofi has shown strong growth in 2023, with an 11.9% YoY increase in EPS and a target of $10 billion in sales. The share price has risen nearly 10% YTD. The company's margins are impressive, with gro
Sanofi (SNY), AstraZeneca's RSV Antibody Gets FDA Nod in Infants
12:50pm, Tuesday, 18'th Jul 2023
Following FDA approval, Sanofi (SNY)/AstraZeneca's (AZN) Beyfortus is the first RSV antibody approved to protect all infants. The companies plan to make it available ahead of the upcoming RSV season.
Ford EV price cuts, Tesla exec compensation settlement, FDA-approved RSV vaccine: July 17, 2023
06:45pm, Monday, 17'th Jul 2023
Yahoo Finance Akiko Fujita reports the top stories for Monday July 17, 2023 including Ford cutting the price on the F-150 Lightning, Tesla directors settling a compensation lawsuit, and the FDA approv
FDA Approves Antibody For RSV After Challenging 2022 Season
01:32pm, Monday, 17'th Jul 2023
RSV in infants often leads to the development of pneumonia or bronchiolitis—conditions that can result in emergency visits.
FDA Approves First RSV Drug to Protect All Infants
01:13pm, Monday, 17'th Jul 2023
While the virus often leads to mild, coldlike symptoms, it is the leading cause of hospitalization of infants in the U.S.
FDA approves AstraZeneca, Sanofi shot that protects infants and toddlers against RSV
01:12pm, Monday, 17'th Jul 2023US FDA approves Sanofi-AstraZeneca's preventive RSV therapy for babies
01:07pm, Monday, 17'th Jul 2023
U.S. Food and Drug Administration said on Monday it had approved Sanofi and partner AstraZeneca's antibody therapy to prevent respiratory syncytial virus (RSV) in infants and toddlers.
This is Why Sanofi (SNY) is a Great Dividend Stock
01:17pm, Tuesday, 11'th Jul 2023
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Sanofi (SNY) have what it takes?
International Wide-Moat Stocks On Sale - The July 2023 Heat Map
11:07am, Friday, 07'th Jul 2023
Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of th
Sanofi reaffirms target to deliver over $10.9 bln in annual vaccine sales by 2030
01:51am, Thursday, 29'th Jun 2023
French drugmaker Sanofi on Thursday reaffirmed its ambition to deliver more than 10 billion euros ($10.89 billion)in annual vaccines sales by 2030, driven by core franchises of influenza, meningitis,
Sanofi says it's back to the drawing board on mRNA flu vaccines
01:35am, Thursday, 29'th Jun 2023
Sanofi said that trials show the currently available mRNA technology behind the most successful COVID-19 shots will not be effective against influenza and it is already working on a next generation of
Sanofi (SNY) Atopic Dermatitis Drug Meets Goals in Phase II Study
06:52pm, Wednesday, 28'th Jun 2023
Sanofi's (SNY) phase II study, investigating amlitelimab for moderate-to-severe atopic dermatitis in adults, meets the primary endpoint.
